Novartis AG Lichtstrasse 35 Basel,
4002 Switzerland - Map Phone: 41 61 324 11 11 Fax: 41 61 324 80 01 Website: http://www.novartis.com
Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The companys Alcon division provides various eye care products consisting of ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye, and over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers prescription medicines, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates, primarily antibiotics; protein or biotechnology-based products; and cytotoxic products for the hospital market, as well as offer biotech manufacturing services to other companies. The companys Vaccines and Diagnostics division provides human vaccines and blood testing and molecular diagnostics products. This division sells influenza, meningococcal, pediatric, and traveler vaccines; and nucleic acid technology blood-screening products to prevent the spread of infectious diseases. The companys Consumer Health division consists of two divisions, including over-the-counter medicines that offer readily available consumer medicines; and Animal Health, which provides veterinary products for farm and companion animals. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland. Key Statistics
| |
| | Pay | Exercised | Mr. Daniel L. Vasella M.D.,
58 Chairman and Member of Chairmans Committee | 4.92M | N/A | Mr. Joseph Jimenez MBA,
52 Chief Exec. Officer | 4.13M | N/A | Mr. Jonathan Symonds C.B.E.,
52 Chief Financial Officer | 1.96M | N/A | Mr. David Epstein B.Sc., M.B.A.,
50 Division Head of Novartis Pharmaceuticals | 2.31M | N/A | Mr. George Gunn BVM&S, DVSM, MRCVS.,
61 Head of Animal Health and Head of Corp. Responsibility | 1.69M | N/A |
|
| | Amounts are as of Dec 31, 2011 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|